The Food and Drug Administration’s fast-track drug approval process is under scrutiny following criticism of the way it approved a controversial Alzheimer’s drug.
Here & Now‘s Scott Tong talks with STAT’s Nicholas Florko.
This article was originally published on WBUR.org.
Copyright 2021 NPR. To see more, visit https://www.npr.org.